Targeted Oncology20 分钟
Novel immunotherapy FK-PC101 Explored in Prostate Cancer Trial
The phase 2 CELLVX-230 trial is assessing the potential of FK-PC101 to prevent prostate cancer recurrence and delay ...
Le Lézard13 分钟
Imbrium Therapeutics Completes First Patient Dosed in Phase 2 Study to Evaluate Sunobinop ...
Imbrium Therapeutics L.P. ("Imbrium"), a subsidiary of Purdue Pharma L.P. ("Purdue"), today announced the first patient has been randomized and dosed in a Phase 2 clinical study evaluating sunobinop ...